blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3558989

EP3558989 - TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES AS IMMUNOMODULATORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  18.02.2022
Database last updated on 11.04.2026
FormerThe patent has been granted
Status updated on  12.03.2021
FormerGrant of patent is intended
Status updated on  28.10.2020
FormerExamination is in progress
Status updated on  01.05.2020
FormerRequest for examination was made
Status updated on  27.09.2019
FormerThe international publication has been made
Status updated on  30.06.2018
Formerunknown
Status updated on  24.01.2018
Most recent event   Tooltip19.12.2025Lapse of the patent in a contracting state
New state(s): TR		published on 21.01.2026  [2026/04]
Applicant(s)For all designated states
Incyte Corporation
1801 Augustine Cut-Off
Wilmington, DE 19803 / US
[2019/44]
Inventor(s)01 / WU, Liangxing
Incyte Corporation
1801 Augustine Cut-Off
Wilmington, Delaware 19803 / US
02 / SHEN, Bo
Incyte Corporation
1801 Augustine Cut-Off
Wilmington, Delaware 19803 / US
03 / XU, Meizhong
Incyte Corporation
1801 Augustine Cut-Off
Wilmington, Delaware 19803 / US
04 / YAO, Wenqing
Incyte Corporation
1801 Augustine Cut-Off
Wilmington, Delaware 19803 / US
 [2019/44]
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[N/P]
Former [2019/44]Warner, James Alexander
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
Application number, filing date17829552.321.12.2017
[2019/44]
WO2017US67904
Priority number, dateUS201662438001P22.12.2016         Original published format: US 201662438001 P
US201762487341P19.04.2017         Original published format: US 201762487341 P
[2019/44]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018119236
Date:28.06.2018
Language:EN
[2018/26]
Type: A1 Application with search report 
No.:EP3558989
Date:30.10.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 28.06.2018 takes the place of the publication of the European patent application.
[2019/44]
Type: B1 Patent specification 
No.:EP3558989
Date:14.04.2021
Language:EN
[2021/15]
Search report(s)International search report - published on:EP28.06.2018
ClassificationIPC:C07D471/04, A61K31/437, A61P37/00, C07D513/04
[2020/45]
CPC:
C07D471/04 (EP,US); A61P37/00 (EP,US); A61P37/04 (EP,US);
C07D513/04 (EP,US)
Former IPC [2019/44]C07D471/04, A61P37/00, A61K31/437
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/44]
Extension statesBA16.07.2019
ME16.07.2019
Validation statesMA16.07.2019
MD16.07.2019
TN16.07.2019
TitleGerman:TRIAZOLO[1,5-A]PYRIDIN-DERIVATE ALS IMMUNMODULATOREN[2019/44]
English:TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES AS IMMUNOMODULATORS[2019/44]
French:DÉRIVÉS DE TRIAZOLO[1,5-A]PYRIDINE EN TANT QU'IMMUNOMODULATEURS[2019/44]
Entry into regional phase16.07.2019National basic fee paid 
16.07.2019Designation fee(s) paid 
16.07.2019Examination fee paid 
Examination procedure16.07.2019Examination requested  [2019/44]
16.07.2019Date on which the examining division has become responsible
02.03.2020Amendment by applicant (claims and/or description)
07.05.2020Despatch of a communication from the examining division (Time limit: M04)
17.09.2020Reply to a communication from the examining division
29.10.2020Communication of intention to grant the patent
08.03.2021Fee for grant paid
08.03.2021Fee for publishing/printing paid
08.03.2021Receipt of the translation of the claim(s)
Opposition(s)17.01.2022No opposition filed within time limit [2022/12]
Fees paidRenewal fee
27.12.2019Renewal fee patent year 03
28.12.2020Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU21.12.2017
AL14.04.2021
AT14.04.2021
CY14.04.2021
CZ14.04.2021
DK14.04.2021
EE14.04.2021
FI14.04.2021
HR14.04.2021
LT14.04.2021
LV14.04.2021
MC14.04.2021
MK14.04.2021
MT14.04.2021
NL14.04.2021
PL14.04.2021
RO14.04.2021
RS14.04.2021
SE14.04.2021
SI14.04.2021
SK14.04.2021
SM14.04.2021
TR14.04.2021
BG14.07.2021
NO14.07.2021
GR15.07.2021
IS14.08.2021
PT16.08.2021
LU21.12.2021
BE31.12.2021
CH31.12.2021
LI31.12.2021
[2026/04]
Former [2024/42]HU21.12.2017
AL14.04.2021
AT14.04.2021
CY14.04.2021
CZ14.04.2021
DK14.04.2021
EE14.04.2021
FI14.04.2021
HR14.04.2021
LT14.04.2021
LV14.04.2021
MC14.04.2021
MK14.04.2021
MT14.04.2021
NL14.04.2021
PL14.04.2021
RO14.04.2021
RS14.04.2021
SE14.04.2021
SI14.04.2021
SK14.04.2021
SM14.04.2021
BG14.07.2021
NO14.07.2021
GR15.07.2021
IS14.08.2021
PT16.08.2021
LU21.12.2021
BE31.12.2021
CH31.12.2021
LI31.12.2021
Former [2024/23]HU21.12.2017
AL14.04.2021
AT14.04.2021
CY14.04.2021
CZ14.04.2021
DK14.04.2021
EE14.04.2021
FI14.04.2021
HR14.04.2021
LT14.04.2021
LV14.04.2021
MC14.04.2021
MK14.04.2021
NL14.04.2021
PL14.04.2021
RO14.04.2021
RS14.04.2021
SE14.04.2021
SI14.04.2021
SK14.04.2021
SM14.04.2021
BG14.07.2021
NO14.07.2021
GR15.07.2021
IS14.08.2021
PT16.08.2021
LU21.12.2021
BE31.12.2021
CH31.12.2021
LI31.12.2021
Former [2023/33]HU21.12.2017
AL14.04.2021
AT14.04.2021
CY14.04.2021
CZ14.04.2021
DK14.04.2021
EE14.04.2021
FI14.04.2021
HR14.04.2021
LT14.04.2021
LV14.04.2021
MC14.04.2021
NL14.04.2021
PL14.04.2021
RO14.04.2021
RS14.04.2021
SE14.04.2021
SI14.04.2021
SK14.04.2021
SM14.04.2021
BG14.07.2021
NO14.07.2021
GR15.07.2021
IS14.08.2021
PT16.08.2021
LU21.12.2021
BE31.12.2021
CH31.12.2021
LI31.12.2021
Former [2023/30]AL14.04.2021
AT14.04.2021
CY14.04.2021
CZ14.04.2021
DK14.04.2021
EE14.04.2021
FI14.04.2021
HR14.04.2021
LT14.04.2021
LV14.04.2021
MC14.04.2021
NL14.04.2021
PL14.04.2021
RO14.04.2021
RS14.04.2021
SE14.04.2021
SI14.04.2021
SK14.04.2021
SM14.04.2021
BG14.07.2021
NO14.07.2021
GR15.07.2021
IS14.08.2021
PT16.08.2021
LU21.12.2021
BE31.12.2021
CH31.12.2021
LI31.12.2021
Former [2023/03]AL14.04.2021
AT14.04.2021
CZ14.04.2021
DK14.04.2021
EE14.04.2021
FI14.04.2021
HR14.04.2021
LT14.04.2021
LV14.04.2021
MC14.04.2021
NL14.04.2021
PL14.04.2021
RO14.04.2021
RS14.04.2021
SE14.04.2021
SI14.04.2021
SK14.04.2021
SM14.04.2021
BG14.07.2021
NO14.07.2021
GR15.07.2021
IS14.08.2021
PT16.08.2021
LU21.12.2021
BE31.12.2021
CH31.12.2021
LI31.12.2021
Former [2023/01]AL14.04.2021
AT14.04.2021
CZ14.04.2021
DK14.04.2021
EE14.04.2021
FI14.04.2021
HR14.04.2021
LT14.04.2021
LV14.04.2021
MC14.04.2021
NL14.04.2021
PL14.04.2021
RO14.04.2021
RS14.04.2021
SE14.04.2021
SI14.04.2021
SK14.04.2021
SM14.04.2021
BG14.07.2021
NO14.07.2021
GR15.07.2021
IS14.08.2021
PT16.08.2021
LU21.12.2021
BE31.12.2021
Former [2022/46]AL14.04.2021
AT14.04.2021
CZ14.04.2021
DK14.04.2021
EE14.04.2021
FI14.04.2021
HR14.04.2021
LT14.04.2021
LV14.04.2021
MC14.04.2021
NL14.04.2021
PL14.04.2021
RO14.04.2021
RS14.04.2021
SE14.04.2021
SI14.04.2021
SK14.04.2021
SM14.04.2021
BG14.07.2021
NO14.07.2021
GR15.07.2021
IS14.08.2021
PT16.08.2021
LU21.12.2021
Former [2022/33]AL14.04.2021
AT14.04.2021
CZ14.04.2021
DK14.04.2021
EE14.04.2021
FI14.04.2021
HR14.04.2021
LT14.04.2021
LV14.04.2021
MC14.04.2021
NL14.04.2021
PL14.04.2021
RO14.04.2021
RS14.04.2021
SE14.04.2021
SI14.04.2021
SK14.04.2021
SM14.04.2021
BG14.07.2021
NO14.07.2021
GR15.07.2021
IS14.08.2021
PT16.08.2021
Former [2022/29]AL14.04.2021
AT14.04.2021
CZ14.04.2021
DK14.04.2021
EE14.04.2021
FI14.04.2021
HR14.04.2021
LT14.04.2021
LV14.04.2021
NL14.04.2021
PL14.04.2021
RO14.04.2021
RS14.04.2021
SE14.04.2021
SI14.04.2021
SK14.04.2021
SM14.04.2021
BG14.07.2021
NO14.07.2021
GR15.07.2021
IS14.08.2021
PT16.08.2021
Former [2022/26]AL14.04.2021
AT14.04.2021
CZ14.04.2021
DK14.04.2021
EE14.04.2021
FI14.04.2021
HR14.04.2021
LT14.04.2021
LV14.04.2021
NL14.04.2021
PL14.04.2021
RO14.04.2021
RS14.04.2021
SE14.04.2021
SK14.04.2021
SM14.04.2021
BG14.07.2021
NO14.07.2021
GR15.07.2021
IS14.08.2021
PT16.08.2021
Former [2022/23]AT14.04.2021
CZ14.04.2021
DK14.04.2021
EE14.04.2021
FI14.04.2021
HR14.04.2021
LT14.04.2021
LV14.04.2021
NL14.04.2021
PL14.04.2021
RO14.04.2021
RS14.04.2021
SE14.04.2021
SK14.04.2021
SM14.04.2021
BG14.07.2021
NO14.07.2021
GR15.07.2021
IS14.08.2021
PT16.08.2021
Former [2022/10]AT14.04.2021
CZ14.04.2021
DK14.04.2021
EE14.04.2021
FI14.04.2021
HR14.04.2021
LT14.04.2021
LV14.04.2021
NL14.04.2021
PL14.04.2021
RO14.04.2021
RS14.04.2021
SE14.04.2021
SK14.04.2021
SM14.04.2021
BG14.07.2021
NO14.07.2021
GR15.07.2021
PT16.08.2021
IS22.12.2021
Former [2022/09]AT14.04.2021
CZ14.04.2021
DK14.04.2021
FI14.04.2021
HR14.04.2021
LT14.04.2021
LV14.04.2021
NL14.04.2021
PL14.04.2021
RO14.04.2021
RS14.04.2021
SE14.04.2021
SK14.04.2021
SM14.04.2021
BG14.07.2021
NO14.07.2021
GR15.07.2021
IS14.08.2021
PT16.08.2021
Former [2022/08]AT14.04.2021
CZ14.04.2021
DK14.04.2021
FI14.04.2021
HR14.04.2021
LT14.04.2021
LV14.04.2021
NL14.04.2021
PL14.04.2021
RS14.04.2021
SE14.04.2021
SM14.04.2021
BG14.07.2021
NO14.07.2021
GR15.07.2021
IS14.08.2021
PT16.08.2021
Former [2022/07]AT14.04.2021
FI14.04.2021
HR14.04.2021
LT14.04.2021
LV14.04.2021
NL14.04.2021
PL14.04.2021
RS14.04.2021
SE14.04.2021
SM14.04.2021
BG14.07.2021
NO14.07.2021
GR15.07.2021
IS14.08.2021
PT16.08.2021
Former [2021/52]AT14.04.2021
FI14.04.2021
HR14.04.2021
LT14.04.2021
LV14.04.2021
NL14.04.2021
PL14.04.2021
RS14.04.2021
SE14.04.2021
BG14.07.2021
NO14.07.2021
GR15.07.2021
IS14.08.2021
PT16.08.2021
Former [2021/51]AT14.04.2021
FI14.04.2021
HR14.04.2021
LT14.04.2021
LV14.04.2021
NL14.04.2021
RS14.04.2021
SE14.04.2021
BG14.07.2021
NO14.07.2021
GR15.07.2021
IS14.08.2021
PT16.08.2021
Former [2021/50]AT14.04.2021
FI14.04.2021
HR14.04.2021
LT14.04.2021
LV14.04.2021
NL14.04.2021
SE14.04.2021
BG14.07.2021
NO14.07.2021
GR15.07.2021
PT16.08.2021
Former [2021/49]AT14.04.2021
FI14.04.2021
HR14.04.2021
LT14.04.2021
LV14.04.2021
NL14.04.2021
SE14.04.2021
BG14.07.2021
NO14.07.2021
GR15.07.2021
Former [2021/47]AT14.04.2021
FI14.04.2021
LT14.04.2021
NL14.04.2021
BG14.07.2021
Former [2021/46]AT14.04.2021
FI14.04.2021
LT14.04.2021
Cited inInternational search[IP] WO2017070089  (INCYTE CORP et al.)
 [E] WO2018026971  (ARISING INT LLC et al.)
 [A]   TRYFON ZARGANES-TZITZIKAS ET AL: "Inhibitors of programmed cell death 1 (PD-1): a patent review (2010-2015)", EXPERT OPINION ON THERAPEUTIC PATENTS., vol. 26, no. 9, 19 September 2016 (2016-09-19), GB, pages 973 - 977, XP055394015, ISSN: 1354-3776, DOI: 10.1080/13543776.2016.1206527

DOI:   http://dx.doi.org/10.1080/13543776.2016.1206527
by applicantWO0200196
   POSTOW ET AL., J. CLINICAL ONCOLOGY, 2015, pages 1 - 9
   GREENWALD ET AL., ANNU. REV. IMMUNOL, vol. 23, 2005, pages 515 - 548
   OKAZAKI; HONJO, TRENDS IMMUNOL, vol. 4, 2006, pages 195 - 201
   SHARPE ET AL., NAT IMMUNOL, vol. 8, 2007, pages 239 - 245
   POSTOW ET AL., J. CLINICAL ONCOL, 2015, pages 1 - 9
   PARRY ET AL., MOL CELL BIOL, 2005, pages 9543 - 9553
   LATCHMAN ET AL., NAT IMMUNOL, vol. 2, 2001, pages 261 - 268
   IWAI ET AL., PNAS2002, vol. 99, no. 19, pages 12293 - 7
   BLANK ET AL., CANCER RES, vol. 64, no. 3, 2004, pages 1140 - 5
   WANG ET AL., EUR J SURG ONCOL, 2015
   HUANG ET AL., ONCOL REP, 2015
   SABATIER ET AL., ONCOTARGET, vol. 6, no. 7, 2015, pages 5449 - 5464
   NAKAE ET AL., J IMMUNOL, vol. 177, 2006, pages 566 - 73
   CARTER ET AL., EUR J IMMUNOL, vol. 32, no. 3, 2002, pages 634 - 43
   FREEMAN ET AL., J EXP MED, vol. 192, no. 7, 2000, pages 1027 - 34
   NISHIMURA ET AL., IMMUNITY, vol. 11, 1999, pages 141 - 151
   NISHIMURA ET AL., SCIENCE, vol. 291, 2001, pages 319 - 322
   BARBER ET AL., NATURE, vol. 439, 2006, pages 682 - 7
   "Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING COMPANY, pages: 1418
   BERGE ET AL., J. PHARM. SCI., vol. 66, no. 1, 1977, pages 1 - 19
   STAHL ET AL.: "Handbook of Pharmaceutical Salts: Properties, Selection, and Use", 2002, WILEY
   KOCIENSKI: "Protecting Groups", 2007, THIEME
   ROBERTSON: "Protecting Group Chemistry", 2000, OXFORD UNIVERSITY PRESS
   SMITH ET AL.: "March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", 2007, WILEY
   PETURSSION ET AL.: "Protecting Groups in Carbohydrate Chemistry", J. CHEM. EDUC., vol. 74, no. 11, 1997, pages 1297
   WUTS ET AL.: "Protective Groups in Organic Synthesis", 2006, WILEY
   K. BLOM: "Two-Pump At Column Dilution Configuration for Preparative LC-MS", J. COMBI. CHEM., vol. 4, 2002, pages 295 - 301
   BLOM ET AL.: "Optimizing Preparative LC-MS Configurations and Methods for Parallel Synthesis Purification", J. COMBI. CHEM., vol. 5, no. 6, 2003, pages 70 - 83
   BLOM ET AL.: "Preparative LC-MS Purification: Improved Compound Specific Method Optimization", J. COMBI. CHEM., vol. 6, 2004, pages 874 - 883
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.